Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics
←Back to story

Lilly to buy Calytrix Bio for up to $1.5 billion | Reuters

ReutersView source article

Part of story

Eli Lilly acquires Calytrix Bio for up to $1.5B in rare blood cancer push

Eli Lilly agreed to acquire Calytrix Bio for up to $1.5 billion to expand development of treatments for rare blood cancers known as myeloproliferative neoplasms, its 14th or 15th acquisition of 2026.

Nov 16, 2026·3 sourcesMergers & acquisitions (M&A)Biotech startupMergers and acquisitionsEli LillyDrug developmentHematology & Blood CancersCancer & OncologyPharmaceutical IndustryRare diseases
Eli Lilly acquires Calytrix Bio for up to $1.5B in rare blood cancer push
00

Other sources for this story

BioPharma Dive

Lilly adds to buyout streak with $1.5B purchase of startup Calytrix

Bloomberg

Eli Lilly to Acquire Calytrix Bio in Deal Worth Up to $1.5 Billion